Evidence map›Paper›PMID 39620653›Full record

ReviewImmunotherapy2024

Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.

Alexander Röth, Austin G Kulasekararaj, Phillip Scheinberg, Jun-Ichi Nishimura

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexander RöthDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-4414-7699
Austin G KulasekararajDepartment of Hematological Medicine, King's College Hospital, London, UK.ORCID 0000-0003-3180-3570
Phillip ScheinbergDivision of Hematology, Hospital A, Beneficência Portuguesa, São Paulo, Brazil.ORCID 0000-0002-9047-4538
Jun-Ichi NishimuraDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0001-5026-693X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, rare, life-threatening hematopoietic stem cell disorder that causes stem cell-derived cells to be vulnerable to complement-mediated lysis and manifests as hemolytic anemia, thrombosis, and peripheral blood cytopenias. C5 inhibitors, eculizumab, and ravulizumab, are recognized as the current standard of care for PNH treatment in countries where they are available. Crovalimab (PiaSky®), which is approved for the treatment of PNH, is a novel anti-C5 inhibitor with an every-4-weeks, low-volume, subcutaneous maintenance dosing regimen with the possibility for self-administration. Data from three phase III studies highlight the overall favorable benefit-risk profile of crovalimab, showing that crovalimab has promising potential to address the unmet medical and socioeconomic challenges in the PNH treatment landscape.

Indexed as

Antibodies, Monoclonal, HumanizedComplement C5Complement Inactivating AgentsHemoglobinuria, ParoxysmalHumansAntibodies, Monoclonal, HumanizedComplement C5Complement Inactivating Agentsanti-C5 recycling monoclonal antibodycomplement inhibitorCrovalimabevery-4-weeks dosingparoxysmal nocturnal hemoglobinuriaPNHsubcutaneous self-administration

Identifiers

PMID39620653
PMCPMC11760285

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.